Neurocrine Biosciences, Inc. (NBIX) News
Filter NBIX News Items
NBIX News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
NBIX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest NBIX News From Around the Web
Below are the latest news stories about NEUROCRINE BIOSCIENCES INC that investors may wish to consider to help them evaluate NBIX as an investment opportunity.
Exploring High Growth Tech Stocks in January 2025The United States market has remained flat over the past week but has experienced a notable 23% increase over the last year, with earnings anticipated to grow by 15% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability, aligning well with current market conditions and future earnings expectations. |
Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & MetabolismNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a narrative review discussing the challenges of traditional treatment of classic congenital adrenal hyperplasia (CAH) with glucocorticoids (GCs) alone and the potential benefits of introducing novel non-GC mechanisms for treating the condition that may enable lower, more physiologic GC dosing. The publication appears in Expert Review of Endocrinology & Metabolism. |
Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNeurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 43rd Annual J.P. Morgan Healthcare Conference at 8:15 a.m. Pacific Time on Monday January 13, 2025 in San Francisco. Kyle Gano, Chief Executive Officer, will present at the conference. |
Neurocrine Biosciences Stock Sees RS Rating UpgradeA Relative Strength Rating upgrade for Neurocrine Biosciences shows improving technical performance. Will it continue? |
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last?Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. |
Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal HyperplasiaNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced CRENESSITY™ (crinecerfont) is now commercially available in the United States. CRENESSITY was recently approved by the U.S. Food and Drug Administration as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH). |
Neurocrine Jumps After Snagging FDA Approval For A First-In-Decades DrugNeurocrine Biosciences stock jumped Monday after the company won FDA approval for the first new treatment for an adrenal disease in decade |
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster PotentialOn Friday, the FDA approved Neurocrine Biosciences, Inc.(NASDAQ:NBIX) Crenessity (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH). CAH is a rare, inherited disorder that affects the adrenal glands and causes them to be larger than normal. The adrenal glands are located above the kidneys and produce hormones that regul |
Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal HyperplasiaNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved CRENESSITY™ (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH), a rare, serious and lifelong genetic condition involving the adrenal glands. CRENESSITY, a potent and selective oral corticotropin-releasing facto |
Exploring Three High Growth Tech Stocks In The United StatesOver the last 7 days, the United States market has remained flat, yet it is up 30% over the past year with earnings forecasted to grow by 15% annually. In this context of robust growth potential, identifying high growth tech stocks that align with these positive trends can be key for investors seeking opportunities in an evolving market landscape. |